| Literature DB >> 32948973 |
Lin Wang1, Junke Song1, Ailin Liu1, Bin Xiao2, Sha Li1, Zhang Wen1, Yang Lu1, Guanhua Du3.
Abstract
Flavonoids are now considered as an indispensable component in a variety of nutraceutical and pharmaceutical applications. Most recent researches have focused on the health aspects of flavonoids for humans. Especially, different flavonoids have been investigated for their potential antiviral activities, and several natural flavonoids exhibited significant antiviral properties both in vitro and in vivo. This review provides a survey of the literature regarding the evidence for antiviral bioactivities of natural flavonoids, highlights the cellular and molecular mechanisms of natural flavonoids on viruses, and presents the details of most reported flavonoids. Meanwhile, future perspectives on therapeutic applications of flavonoids against viral infections were discussed.Entities:
Keywords: Antiviral bioactivities; Cellular and molecular mechanisms; Natural flavonoids; Therapeutic applications
Year: 2020 PMID: 32948973 PMCID: PMC7500501 DOI: 10.1007/s13659-020-00257-x
Source DB: PubMed Journal: Nat Prod Bioprospect ISSN: 2192-2209
Fig. 1The basic scaffolds of flavonoids. a The scaffold of flavanones and catechins; b the scaffold of the flavones and flavonols; c the scaffold of isoflavone; d the scaffold of anthocyanins. The structures of aurones and biflavones were not involved in this figure since their structures containing some special elements which were described in the article
Fig. 2Literature review on the antiviral activities of natural flavonoids
The different viruses which inhibited by various flavonoids
| Viruses | Model | Flavonoids | References |
|---|---|---|---|
| Influenza virus | MDCK cells | Gallocatechin-7-gallate, catechins, apigenin, luteolin, 3-deoxysappanchalcone, scutellarin, galuteolin, vitexin, chrysin, kaempferol, quercetin, myricetin, rhamnocitrin, rutin, daidzein, genistein, sappanchalcone, baicalein, oroxylin A | Liu et al. [ |
| HBV | Vero cells | Myricetin rhamnoside, myricetin-3-α-O-ramnosil (1 → 6)-α-galactoside, 5,3′-dihydroxy-3,6,7,8,4′- pentamethoxyflavone, 5-hydroxy-3,6,7,3′,4′- pentamethoxyflavone | Ortega et al. [ |
| HCV | Huh-7.5 cells | Epigallocatechin gallate (EGCG), sorbifolin, pedalitin | Mekky et al. [ |
| HIV-1 | CD4+ NKT cells, T cells | Hesperidin, linarin, catechins, genistein, herbacitrin, naringin, formononetin, biochanin A | Nzuza et al. [ |
| HIV-2 | Vero cells | Genistein, formononetin, biochanin A | Patra [ |
| HSV-1 | Vero and CV1 cells | Catechins, genistein,gorvanol A, kaempferol, 5,6,7-trimethoxyflavone, 5,3′-dihydroxy-3,6,7,8,4′- pentamethoxyflavone, 5-hydroxy-3,6,7,3′,4′- pentamethoxyflavone, coumestrol, houttuynoid A, chrysin | Li et al. [ |
| HSV-2 | Vero cells | Genistein, coumestrol, houttuynoid A | Bús et al. [ |
| HPV-1 | Human condyloma, Vero cells | Catechins, 5,3′-dihydroxy-3,6,7,8,4′- pentamethoxyflavone, 5-hydroxy-3,6,7,3′,4′- pentamethoxyflavone | Patra [ |
| DENV-2 | C6/36 Aedes albopictus mosquito cell, hepatocytes (Huh-7) | Quercetin, quercitrin, kaempferitrin, chrysin | Patra [ |
| Sendai virus (SeV) | Mice model | Baicalein | Dou et al. [ |
| Zika virus (ZIKV) | Vero cells | Baicalein, baicalin, pinocembrin, chrysin, myricetin, luteolin, Epigallocatechin gallate, epicatechin gallate, gallocatechin gallate, quercetin-3-β-O- | Oo et al. [ |
| CVB3 | Vero cells | Mosloflavone, oroxylin A, norwogonin, epigallocatechin-3-gallate | Patra [ |
| JEV | A549 cells, BHK21 cells | Epigallocatechin-3-gallate (EGCG), luteolin, kaempferol | Patra [ |
| EBV | Ramos cells | Genistein, quercetin, apigenin, luteolin, baicalein | Granato et al. [ |
| Poliovirus | Vero cells | 5,6,7-Trimethoxyflavone, 3-methylkaempferol, 3(2H)-isoflavene | Ortega et al. [ |
| RSV | Vero cells | Genistein, quercetin, baicalein, baicalin, epigallocatechin-3-gallate, proanthocyanidin | Zhang et al. [ |
| Coronovirus | Vero cells | Quercetin, Luteolin, quercetin, quercetrin, kaempferol glycosides | Patra [ |
| SARS-CoV | 3CL protease activity assay | Daidzein, rutin, genistein, icaritin, genistin, ipriflavone, (−) gallocatechin, (±)-epigallocatechin gallate, puerarin, (−)-epicatechin, glabridin, (±)-catechin, baicalein, diosmin, diosmetin, skullcapflavone II, orientin, acacetin, bacicalin, rhoifolin, hispidulin, sinensetin, oroxin B, pectolinarin, cirsiliol, homoplantaginin, amentoflavone, luteolin, herbaacetin, kaempferol, morin, myricetin, fisetin, quercitrin, queretin, helichrysetin, cardamonin, neodesperidin dishydrochalcone, mangiferin, auraptene | Jo et al. [ |
| Human CMV | HEL 299 cells | Genistein, 5,6,7-Trimethoxyflavone | Patra [ |
| Rotavirus | MA-104 cells, Caco2 cells | Genistein, epigallocatechin Gallate (EGCG), α-glucosyl hesperitin (GH) | Lipson et al. [ |
| Adenovirus | Hep2 cells, SW480 cell, BCC-1/KMC cells | Catechins, genistein, quercetin | Patra [ |
| SARS-CoV-2 | Vero cells | Baicalein, scutellarein, dihydromyricetin, quercetagetin, myricetin | Liu et al. [ |
Fig. 3Potential drug targets (DT) and candidate targets (CT) of flavonoids in the viral life cycle. The viral life cycle can be divided into a sequence of stages (attachment and entry; uncoating, replication, assemble, and exocytosis), each of which is a potential site for pharmacologic intervention. Here we showed potential drug targets (DT) and candidate targets (CT) of antiviral flavonoids
Anti-virus activities of quercetin/IQ
| Virus | Mechanism of action | Dose/concentration | References |
|---|---|---|---|
| A/Udorn/317/72 (H3N2) | Decreases superoxide and LPO associated viral infection | 1 mg/day | Kumar et al. [ |
| Dengue virus | Inhibits virus replication | 20 mg/mL | Keivan Zandi et al. [ |
| Japanese encephalitis virus | Inhibits virus adsorption; Interferes virus replication | IC50 (212.1 μg/mL) | Jefree Johari et al. [ |
| Rhinovirus | Inhibits RV endocytosis and replication and the expression of chemokines and cytokines | 10 μM in vitro; 0.2 mg/kg in vivo | Shyamala Ganesan et al. [ |
| Mayaro virus | Inhibits virus replication | 2 μg/mL | dos Santos et al. [ |
| H1N1, H3N2, and H5N1 | Binds to Influenza hemagglutinin protein; inhibit viral-cell fusion | IC50 (7.756, 6.225, 2.738 μg/mL, respectively) | Wu et al. [ |
| Epstein-Barr virus | Induces EBV gene transcription; reduces EBV latency; increases EBV progeny production; inhibits EBV infection | 62 μM | Lee et al. [ |
| hepatitis C virus | Inhibits HCV replication, specific infectivity; affects virion integrity; hampers the localization of HCV core protein to LDs | 50 μM | Ángela Rojas et al. [ |
| Influenza A H1N1 (A/PR/8/34) | Inhibits neuraminidase | 1.563 μg/mL; 240 mg/kg/days | Liu et al. [ |
Anti-virus activity of baicalin
| Virus | Mechanism of action | Dose/concentration | References |
|---|---|---|---|
| A/FM1/1/47 (H1N1) | Interferes with neuraminidase activity | 1.2 μg/mL | Xu et al. [ |
| Strain A/Thailand/K (H3N2) | Inhibits virus budding and neuraminidases | IC50:49.6 ± 1.07 μg/mL | Gao et al. [ |
| an-1/04 (H5N1) | Interferes with H5N1 replication | IC50:18.79 ± 1.17 μM | Sithisarn et al. [ |
| SARS-CoV | 3CLpro | 0.39 μM | Liu et al. (2020) |
| Zika virus | Inhibits virus replication | 0.004 µM | Oo et al. [ |
| Dengue virus | Inhibits virus replication | IC50:13.5 ± 0.08 μg/mL | Moghaddam et al. [ |
| Sendai virus | Interferes with neuraminidase | 0.70 μg/mL | Dou et al. [ |
| Japanese encephalitis virus | Interactions with the E protein of DENV2 | 14.28 µg/mL | Johari et al. [ |
| CVB3 | Inhibits virus replication | IC50:429.00 ± 22.06 μg/mL | Gao et al. [ |
| Japanese encephalitis virus | Direct virucidal activity | 14.28 µg/mL | Johari et al. [ |
| Human HIV-1 | Inhibits HIV-1 induced syncytium formation, HIV-1 p24 antigen, and HIV-1 RT production; inhibits Env-protein mediated fusion of HIV | 4.3 μM | Fesen et al. [ |
| DENV-2 | Inhibits virus replication | 1.55 μg/mL | Zandi et al. [ |
Anti-virus activity of apigenin
| Virus | Mechanism of action | Dose/concentration | References |
|---|---|---|---|
| EBV | Inhibits expression of EBV lytic proteins, Zta, Rta, EAD, and DNase | 200 to 295 μM (24 h); 69 to 158 μM (48 h) | An et al. [ |
| African swine fever virus | Inhibits ASFV-specific protein synthesis and viral factory formation | IC50:212.1 ± 11.5 μM | Hakobyan et al. [ |
| HCV | Inhibits HCV replication by decreasing mature miR122 expression | 5 μM | Shibata et al. [ |
| SARS-CoV 3CLpro | Inhibits SARS-CoV 3CLpro | 280.8 μM | Ryu et al. [ |
| PEDV | Interferes PEDV replication | Choi et al. [ | |
| FMD virus | Inhibits cytopathogenic effect and FMDV replication | Qian et al. [ | |
| HIV | Inhibits CYP3A4, slowdown elimination of PIs | Kehinde et al. [ | |
| Influenza virus | 1.43 μg/mL | Liu et al. [ | |
| Vaccinia virus | Inhibits VV replication | Chang et al. [ | |
| PV-2 | 12.2–13.3 μM | Visintini Jaime et al. [ |
Anti-virus activity of luteolin
| Virus | Mechanism of action | Dose/concentration | References |
|---|---|---|---|
| DENV | Inhibits proprotein convertase furin | 10 mM 100 mg/kg | Peng et al. [ |
| EBV | Inhibits viral lytic proteins expression and interferes with Sp1 binding to the IE gene promoters | NA cells (IC50 = 8.6–18.1 μM); HA cells (IC50 = 6–12.3 μM); B cells (IC50 = 6-8 μM) | Wu et al. [ |
| Japanese Encephalitis Virus (JEV) | Inhibits JEV replication | IC50 = 4.56 μg/mL | Fan et al. [ |
| Influenza virus A/Jinan/15/90 (H3N2) | Inhibits neuraminidase (NA) activities | IC50 = 7.15 μM | Liu et al. [ |
Influenza virus A/Jiangxi/312/2006 (H3N2) A/Fort Monmouth/1/1947 (H1N1) | Interferes with the virus at the early stages of its lifecycle and blocks influenza virus absorption and internalization | IC50 = 6.89 μM | Yan et al. [ |
| HBV | Inhibits HBV transcription through ERK-mediated downregulation of HNF4α expression | 10–40 μM; 2 mg/kg | Bai et al. [ |
| HIV-1 | Inhibits HIV-1 activity; infection by abrogating Tat-mediated LTR activity | 5–10 μM | Mehla et al. [ |
| SARS-CoV | Binds to the surface spike protein of SARS-CoV and inhibits entry of the virus into host cells | EC50 = 10.6 μM | Yi et al. [ |
| COVID-19 | Inhibits COVID-19 main protease Mpro | Khaerunnisa et al. [ |
Anti-virus activity of isorhamnetin
| Virus | Mechanism of action | Dose/concentration | In vitro | References |
|---|---|---|---|---|
| EV71 virus | Inhibits EV71 RNA replication and protein synthesis | 10 mg/kg | In vivo | Dai et al. [ |
| H1N1 virus | Reduces virus-induced active oxygen production, blocking cytoplasmic lysosomal acidification and lipid formation of microtubule-associated proteins | 1 mg/kg | In vivo | Enkhtaivan et al. [ |
HHV1 virus HHV2 virus | Adheres to the cell surface and reduces the interaction between cells and viruses | 100 g/mL | In vitro | Sochocka et al. [ |
| Zika virus | Inhibits NS3–NS2B protease | 600 µM | Sonam et al. [ |
Anti-virus activity of isoflavones
| Isoflavone | Virus | Mechanism of action | Dose/concentration | References |
|---|---|---|---|---|
| Genistein | Avian leucosis virus | Inhibits the late phase of ALV-J replicative cycle | 12.5–100 μM | Qian et al. [ |
| Porcine reproductive and respiratory syndrome virus (PRRSV) | Activation of adaptive immune system pathways | Smith et al. [ | ||
| Genistein | African swine fever virus | Disrupts viral DNA replication, blocking the transcription of late viral genes as well as the synthesis of late viral proteins, reducing viral progeny | IC50 = 13 μM, | Arabyan et al. [ |
| Genistein | rotavirus | Inhibits rotavirus replication and upregulates AQP4 expression | 80 μM | Huang et al. [ |
| Genistein | Herpes simplex virus | Inhibits virus replication | 40 μM | Argenta et al. [ |
| KIN 101 | hepatitis C virus (HCV) and influenza virus | Activates the ISG54 promoter mediated nuclear translocation of IRF-3 | IC50 = 0.2 μM | Bedard et al. [ |
| Deguelin | Human cytomegalovirus (HCMV) | Suppresses the production of the infectious virus; inhibits the lytic cycle | 250 nM | Nukui et al. [ |
| HIV-1 | Inhibits HIV-1 entry into cell lines, primary human CD4+ T lymphocytes, and macrophages | IC50 = 81.6 ± 4.3 μM | Mediouni et al. [ | |
| Daidzein | Dengue virus type-2 | Inhibits virus replication | IC50 = 142.6 μg/mL | Zandi et al. [ |
Anti-virus activity of catechin/EGCG
| Catechin | Virus | Mechanism of action | Dose/concentration | References |
|---|---|---|---|---|
| EGCG | HBV | Detrimental to HBV replication by altering lysosomal acidification | 25–50 μM | Zhong et al. [ |
| EC, ECG, EGC and EGCG | HSV-1/HSV-2 | Destructive HSV-1 virions;competitively interacted with virion surface proteins | HSV1:IC99 (IC50: 18.3–72.3 μM) HSV2:IC99 (IC50: 12.5–25 μM) | Isaacs et al. [ Colpitts et al. [ |
| EGCG | EBV | Suppressed the synthesis of lytic protein; inhibited the lytic infection; reducing the DNA binding potency of nuclear antigen; inhibition of the MEK/ERK1/2 and PI3-K/Akt signaling pathways | IC50: 250 μM | Weber et al. [ Liu et al. [ |
| EGCG | Adenovirus | Inhibited the attachment of adenovirus by interacting with virion surface proteins | IC50:20 µM | Liu et al. [ |
EGCG, EC ECG | HIV1/HIV2 | Inhibitory action against HIVRT; competitive inhibitors of the template-primer; noncompetitive inhibitors of Dttp; inhibits HIV entry | EGCG:300 mg/kg/day; IC50:3.44 ± 1.07 µM GCG:2.45 ± 0.36 µM | Yamaguchi et al. [ Hartjen et al. [ Rrapo et al. [ |
| EGCG | HCV | Inhibitor of the HCV entry and viral RNA replication | IC50: 17.9 μM | Chen et al. [ |
EGCG, EC ECG | Influenza A/B | Inhibitory effects on the acidification of endosomes and lysosomes; | EC: > 145.09 μg/mL EGC: 30.49 μg/mL EGCG: 56.49 μg/mL | Imanishi [ Yang et al [ |
| EGCG | DENV, JEV and TBEV | Associated with the DENV2 E protein; destruction of the structure of ZIKV virions | > 100 μM | Carneiro et al. [ |
| EGCG | Human T-cell Lymphotropic Virus-1 | Reduce the invasive potential of HTLV-1-positive leukemia cells; suppressing Tax expression; inhibiting the activation of NF-kB pathway and induction of MMP-9 transcription in HTLV-1 positive cells | 25 μM in HuT-102 | Harakeh et al. [ |
EGCG GCC | Rotaviruses enteroviruses | Interfering with virus adsorption; reduced reactive oxygen species (ROS) generation | GCG: 10 μM EGCG:10 μM | Ho et al. [ |
| EGCG | Ebola virus (EBOV) | Reduced the production of new viruses via inhibiting HSPS5 | 10–100 μM | Reid et al. [ |